TABLE 3.
Amino acid usage at positions 33 and 57 for antibodies of C. neoformans which have been evaluated for protective efficacy
| MAb | Isotope | Amino acid at position:
|
Protective | Reference(s) | |
|---|---|---|---|---|---|
| 33 | 57 | ||||
| Consensus | NAa | F | N | NA | 29 |
| 3B10 | IgG1 | F | N | Yes | 29, 33 |
| 2D10 | IgM | F | R | Yes | 29, 32 |
| 2H1 | IgG1 | F | K | Yes | 29, 32 |
| 3E5 | IgG1b | F | N | Yes | 8, 29, 48 |
| 18G9 | IgA | F | K | Yes | 29, 32 |
| 10F10 | IgG1 | F | S | Yes | 29 |
| 12A1 | IgM | F | N | Yes | 29, 31 |
| 17E12 | IgG1 | F | K | Yes | 29 |
| 18B7 | IgG1 | F | K | Yes | 29 |
| 3C2 | IgG1 | L | K | Yes | 5, 30 |
| 471 | IgG1 | L | K | Yes | 5, 30 |
| 13F1 | IgM | Y | S | No | 29, 31 |
| 21D2 | IgM | Y | S | No | 8, 32 |
a
NA, not applicable.
b
The IgG1 switch variant of the nonprotective IgG3 MAb 3E5 is protective (48).